Pharmaron Beijing Co., Ltd.

Climate Impact & Sustainability Data (2023)

Beijing headquarters certified as meeting ISO 14001 requirements in early 2024.
Piloted green electricity and biomass energy application in multiple domestic and overseas campuses, gradually increasing the proportion of renewable energy use.
CDP (Carbon Disclosure Project) climate questionnaire rated B.

Developed and piloted a Diversity and Inclusion program.
Organized a number of academic activities.
Rated as “2023 ESG Industry Top Related Company” in Sustainalytics rating and evaluated as a “low risk” company.
Selected as the “ESG Best Practice Case of Listed Companies” of China Association for Public Companies in 2023.
Won the honors of ESG Top 50 of China’s Listed Companies in 2023 and the 17th Green Low Carbon Outstanding Contribution Award of China’s Listed Companies.

Significant fluctuation of the global financing environment forced the biopharmaceutical industry to enter a major restructuring phase.
Intensified global geopolitical tension put the CRO/CDMO industry under unprecedented pressure.
Impact of global biotech funding environment and the temporary slowdown of the growth of customer demands.

Remained committed to long-term growth strategies and made necessary adjustments for future growth.
Actively expanded customer base, introducing over 800 new customers.
Further enhanced integrated service lines and rapidly expanded into new drug modalities.
Enhanced global operations and contracted more late-stage projects through a unique “hybrid model”.
Continuously invested in AI, green chemistry and “proteomics, gene-editing and HTS integrated technologies”.

Frameworks Used: SBTi, UN Global Compact

Certifications: ISO 14001